Search results for "From ACP Journal Club"
In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia
A reduction in hyperkalemia could allow use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or aldosterone-receptor blockers in at-risk patients, justifying the prescribing of sodium-glucose cotransporter 2 (SGLT2) inhibitors, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/09/16/6.htm
16 Sep 2022
Patients surviving COVID-19 had increased risk for incident diabetes vs. persons without COVID-19
Although the effect of COVID-19 on diabetes incidence is small, according to the study, the affected population could be large, given that many at-risk people have had acute COVID-19, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/08/12/7.htm
12 Aug 2022
In diabetes, some statins reduce non–HDL-C better than others vs. placebo
A review reaffirmed well-known information about the potency of commonly prescribed statins and suggested that non–high-density lipoprotein cholesterol (HDL-C) may be a better measure of cardiovascular risk than low-density lipoprotein cholesterol in patients on statins, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/08/12/6.htm
12 Aug 2022
In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
An analysis of recent manufacturer-sponsored studies of finerenone show it to be a potentially important new treatment for patients with type 2 diabetes and albuminuric chronic kidney disease (CKD), although it poses risk for serious hyperkalemia, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/05/13/6.htm
13 May 2022
Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive class
The results of this individual-patient data meta-analysis suggest that angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers should be first-line antihypertensive agents in patients with prediabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/04/08/7.htm
8 Apr 2022
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status
The combination of efficacy and safety data from a recent placebo-controlled trial and other research shows sodium-glucose cotransporter-2 inhibitors to be an important treatment for heart failure with preserved ejection fraction (HFpEF) regardless of patients' diabetes status, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2022/10/14/6.htm
14 Oct 2022
Some glucose-lowering drugs reduce HbA1c more than others
A recent meta-analysis supports the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in patients with diabetes and elevated cardiovascular risk, but cost remains a barrier, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/8.htm
11 Dec 2020
In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control
Clinicians can use the results of a recent European trial to reassure patients that good glycemic control can be achieved with either device, although real-time monitoring may be beneficial for those with more hypoglycemia issues, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/10/08/7.htm
8 Oct 2021
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/03/11/8.htm
11 Mar 2022
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Once tirzepatide is approved by the FDA, it may be a treatment option for patients with type 2 diabetes who are overweight, have high risk for atherosclerotic cardiovascular (CV) disease, and have no gastrointestinal symptoms, an ACP Journal Club summary said.
https://diabetes.acponline.org/archives/2022/03/11/7.htm
11 Mar 2022